Fairvalue-Calculator Fairvalue-Calculator
EN DE

Initiator Pharma A/S, a clinical stage life science company, (INIT) Fair Value & Analysis

Healthcare · SE · Market cap 197M SEK

Pricekr 2.78
Fair Valuekr 1.94
Upside-30.2%
Quality95/100
Evidence: Low Range kr 1.46 – kr 2.43

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Initiator Pharma A/S, a clinical stage life science company, (INIT) currently trades at kr 2.78, while our model-based Fair Value estimate is kr 1.94 — implying the stock looks roughly 30.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The company also develops IP2016, which is in preclinical development for the treatment of depression and pain; and Pudafensine and IP2018, which is in preclinical development to treat female sexual dysfunction. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Initiator Pharma A/S, a clinical stage life science company, (INIT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 1.94 versus a price of kr 2.78 — about −30% (overvalued). Model-based estimate, not financial advice.
What is the fair value of INIT?
Our 21-model fair value for Initiator Pharma A/S, a clinical stage life science company, is kr 1.94 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 2.78.
What is the quality score of INIT?
Initiator Pharma A/S, a clinical stage life science company, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.